Therefore, targeting how LMP1 dysregulates cellular sumoylation processes by inhibiting the LMP1-Ubc9 interaction or by regulating the induction of sumo-1/2/3 expression may provide a potential method to limit the oncogenesis and progression of EBV-associated lymphomas. The gene discussed is SUMO1; the disease is lymphoma.